Out of Cash and Unable to Pin Down a Partnership, Akceli Shuts Down Operations | GenomeWeb

For the past few weeks, anyone trying to get in contact with microarray developer Akceli has been out of luck — the company’s phones are disconnected, its website is down, and messages to corporate e-mail accounts get bounced back.

As it turns out, the company has folded after being unable to find new investors and failing to generate sufficient revenues to fund operations, according to Rockefeller University researcher Thomas Tuschl, who was a member of Akceli’s scientific advisory board.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.